[Anti-TNF alpha in rheumatoid arthritis].
Thanks to the better understanding of the physiopathological mechanisms in action in rheumatoid arthritis (RA), new therapeutic weapons have appeared, which have dramatically modified our approach of the disease. These so-called "biological" therapies antagonize the action of the cytokine at the top of the cascade which maintains the synovial inflammation, and leads to the joint destruction, i.e. the Tissue Necrosis Factor alpha (TNF alpha). Several controlled clinical studies have clearly demonstrated their short and middle term efficacy and safety profile, and they will soon become at the Belgian clinicians disposal. They have a rapid and dramatic effect on the signs and symptoms of RA and they slow down the radiologic progression. Some questions remain unresolved concerning their place in the general therapeutic strategy against RA, due to the uncertainties of their use in the long run, and to their cost.
Schreiber
S
S
Service de Rhumatologie, Département de Médecine Interne, C.H.U. Tivoli, La Louvière, U.L.B.
Sternon
J
J
D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000191:economics / Q000276:immunology / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000737:chemistry / Q000191:economics / Q000276:immunology / Q000600:supply & distribution / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000276:immunology* / Q000628:therapy*; D001530:Belgium; D018450:Disease Progression; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry / Q000191:economics / Q000276:immunology / Q000627:therapeutic use*; D000069285:Infliximab; D011859:Radiography; D018124:Receptors, Tumor Necrosis Factor / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept